Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation

NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...
November 20, 2025 07:55 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture

SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTLC) today announces that its joint venture partner, GMP Bio, has completed an independent third-party...
November 11, 2025 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics and Sapu Bioscience Announce Publication on Sub-15 nm Nanoparticles in International Journal of Molecular Sciences

Breakthrough Review Defines the Next Frontier in Precision Nanomedicine Agoura Hills, CA, and San Diego, CA, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics Inc. (OTLC) and JV partner Sapu...
October 30, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of...
October 30, 2025 06:00 ET | Source: Oncotelic Therapeutics, Inc.

Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

AGOURA HILLS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative...
October 28, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of...
October 23, 2025 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus)

Accepted Presentations Showcase First-in-Human Development, Manufacturing Innovation, and Predictive Biomarkers for Deciparticle™ Everolimus (Sapu003) AGOURA HILLS, Calif., Oct. 23, 2025 (GLOBE...
October 20, 2025 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic to Present at the LD Micro Main Event XIX

AGOURA HILLS, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative...
October 08, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium

SYDNEY, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – Sapu Nano today announced the presentation of its poster, “Sapu-003: Novel Intravenous Deciparticle™ Everolimus Entering Phase 1 Study...
September 24, 2025 08:30 ET | Source: Oncotelic Therapeutics, Inc.

Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano, developer of Deciparticle™, today announced that it has received approval from Australia’s Human Research Ethics Committee (HREC)...